Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Colorectal Carcinoma

Cancer

Volumn 100, Issue 2, 2004, Pages 279-287

  Bajetta, Emilio ^a   Di Bartolomeo, Maria ^a   Mariani, Luigi ^a   Cassata, Antonio ^a   Artale, Salvatore ^b   Frustaci, Sergio ^c   Pinotti, Graziella ^d   Bonetti, Andrea ^e   Carreca, Ignazio ^f   Biasco, Guido ^g   Bonaglia, Luigi ^h   Marini, Giovanni ⁱ   Iannelli, Antonio ^j   Cortinovis, Diego ^a   Ferrario, Ermina ^a   Beretta, Elena ^a   Lambiase, Antonio ^k   Buzzoni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

^e USL 21   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h Division of Surgery   (Italy)

ⁱ Oncology Unit   (Italy)

^j Medical Oncology Unit   (Italy)

^k ROCHE MILANO RICERCHE   (Italy)

more..

Author keywords

Colorectal carcinoma; First line treatment; Irinotecan and capecitabine combination; Phase II trial

Indexed keywords

CAMPTOTHECIN; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ABDOMINAL PAIN; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSESTHESIA; ERYTHEMA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 9144255466     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11910     Document Type: Article

References (43)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
2. Benson AB 3rd. Therapy for advanced colorectal cancer. Semin Oncol. 1998;25(5 Suppl 11):2-11.
3. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;7:425-432.
4. Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301-308.
5. Meta-analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537-3541.
6. De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808-815.
7. Conley BA, Kaplan RS, Arbuck SG. National Cancer Institute clinical trials program in colorectal cancer. Cancer Chemother Pharmacol. 1998;42:S75-S79.
8. Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995;13:1303-1311.
9. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10:896-903.
10. Thirion P, Wolmark N, Haddad E, et al. Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol. 1999;10:1317-1320.
11. Rustum YM, Cao S. New drugs in therapy of colorectal cancer: preclinical studies. Semin Oncol. 1999;26:612-620.
12. Meropol NJ. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur J Cancer. 1998;34:1509-1513.
13. Pazdur R, Hoff PM, Medgyesy D, et al. The oral fluorouracil prodrugs. Oncology. 1998;12:48-51.
14. Bajetta E, Colleoni M, Di Bartolomeo M, et al. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. J Clin Oncol. 1995;13:2613-2619.
15. Bajetta E, Di Bartolomeo M, Somma L, et al. Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma. Cancer. 1996;78:2087-2093.
16. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291-297.
17. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
18. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.
19. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282-2292.
20. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13:566-575.
21. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996;14:709-715.
22. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19:1501-1518.
23. Pitot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol. 1997;15:2910-2919.
24. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.
25. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
26. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041-1047.
27. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905-914.
28. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol. 2001;19:3801-3807.
29. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
30. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992;35:1505-1509.
31. Pavillard V, Formento P, Rostagno P, et al. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol. 1998;56:1315-1322.
32. Guichard S, Hennebelle I, Bugat R, et al. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol. 1998;55:667-676.
33. Cao S, Hapke G, Rustum YM. Enhanced antitumour activity of xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts [abstract]. Proc Am Assoc Cancer Res. 2001;42:464.
34. Guichard S, Cussac D, Hennebelle I, et al. Sequence-dependence activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer. 1997;73:729-734.
35. DeLord J, Pierga J, Berthault-Cvitkovic F, et al. Dose escalation and pharmacokinetic study of capecitabine and irinotecan (CPT-11) in gastro-intestinal (GI) tumors [abstract]. Eur J Cancer. 2001;37:76.
36. Schleucher N, Tewes M, Achterrath W, et al. Extended phase I study of capecitabine and weekly irinotecan as first-line chemotherapy in metastatic colorectal cancer [abstract]. Eur J Cancer. 2001;37:290.
37. Bajetta E, Cortinovis D, Cassata A, et al. Activity and safety of capecitabine and irinotecan (CTP-11) in association as first-line chemotherapy in advanced colorectal cancer [abstract]. Eur J Cancer. 2001;37:293.
38. World Health Organization. Handbook for reporting results of cancer treatment. Publication No 48. Geneva: World Health Organization, 1979.
39. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials. 1989;10:1-10.
40. Kerr DJ, Ten Bokkel Huinink WW, Bakker J, et al. CPT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (MCRC): preliminary results of a phase I/II study [abstract]. Eur J Cancer. 2001;37:296.
41. Bomer MM, Dietrich D, Popescu R, et al. A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first line treatment of metastatic colorectal cancer (MCC) [abstract]. J Clin Oncol. 2003;22:1068.
42. Diaz-Rubio E, Evans TR, Tabemero J, et al. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. Ann Oncol. 2002;13:558-565.
43. Dunst J, Reese T, Sutter T, et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 2002;20:3983-3991.